ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Mark I. Block
Joel D. Cooper
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Block, M. I.
Right arrow Articles by Cooper, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Block, M. I.
Right arrow Articles by Cooper, J. D.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1997;64:770-776
© 1997 The Society of Thoracic Surgeons

Original Article: General Thoracic

Improvement in Staging of Esophageal Cancer With the Addition of Positron Emission Tomography

Mark I. Block, MD, G. Alexander Patterson, MD, R. Sudhir Sundaresan, MD, Marci S. Bailey, RN, Fidelma L. Flanagan, MD, Farrokh Dehdashti, MD, Barry A. Siegel, MD, Joel D. Cooper, MD

Division of Cardiothoracic Surgery, Department of Surgery, and Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

Background. Positron emission tomography with the glucose analogue 2-[18F]fluoro-2-deoxy-D-glucose (FDG) has been used to detect and stage a variety of malignancies. We hypothesized that FDG–positron emission tomography would improve staging of patients with esophageal cancer and thereby facilitate selection of candidates for resection.

Methods. Fifty-eight patients (42 men and 16 women) with biopsy-proven esophageal cancer were evaluated with both FDG–positron emission tomography and computed tomography.

Results. In all but 2 patients, increased FDG uptake was identified at the site of the primary tumor. Six patients were not operative candidates. Seventeen patients were not candidates for resection because of metastatic disease. Positron emission tomography identified the metastatic disease in all 17 (12 of whom underwent confirmatory biopsy), whereas computed tomography was positive for metastases in only 5. The remaining 35 patients underwent surgical exploration, were judged to have resectable disease and had esophagectomy. Pathologic examination of resected specimens identified lymph node metastases in 21 patients. These nodes were detected by positron emission tomography in 11 patients and by computed tomography in 6.

Conclusions. Positron emission tomography improved staging and facilitated selection of patients for operation by detecting distant disease not identified by computed tomography alone.


Related Article

Discussion
Ann. Thorac. Surg. 1997 64: 776-777. [Extract] [Full Text]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.